<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03349931</url>
  </required_header>
  <id_info>
    <org_study_id>K-170102</org_study_id>
    <secondary_id>2017-A01518-45</secondary_id>
    <nct_id>NCT03349931</nct_id>
  </id_info>
  <brief_title>Prospective Multicenter Evaluation of the MycoGenie Kit for the Diagnosis of Invasive Aspergillosis</brief_title>
  <acronym>MYCOGENIE</acronym>
  <official_title>Prospective Multicenter Evaluation of the MycoGenie Kit for the Diagnosis of Invasive Aspergillosis in Hematological Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Société ADEMTECH SA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the performances of the real-time PCR ADEMTECH kit
      of DNA extraction and detection of Aspergillus fumigatus in serum samples in patients at
      high-risk for invasive aspergillosis (IA). DNA detection will be associated with detection of
      TR34/L98H mutations in cyp51A gene, which confer azole resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Accurate diagnosis of invasive pulmonary aspergillosis (IPA) in patients at high risk of
      invasive fungal infection remains challenging due to difficulties in differentiating IPA from
      pulmonary infections caused by other molds or bacteria on clinical and radiological grounds.
      Therefore, culture-based microbiological diagnosis is of primary importance but requires
      semi-invasive or invasive procedures, such as bronchoalveolar Lavage (BAL) or
      computed-tomography (CT)-guided needle biopsy.

      Alternate diagnostic methods include the detection of biomarkers, such as fungal antigens
      (Aspergillus galactomannan [GM]) or DNA released by Aspergillus hyphae in host tissues. These
      biomarkers are well recognized as early IPA predictors Recently, several clinical evaluations
      to detect Aspergillus DNA, either in respiratory or in blood-based samples, have clearly
      shown the diagnostic value of this biomarker. In addition, methodological recommendations
      have been established for PCR protocols, and different standardized Aspergillus quantitative
      PCR (qPCR) kits have been commercialized. These recent advances show that PCR is now mature
      for routine use in clinical settings.

      Another issue is the emergence of aspergillosis due to azole-resistant isolates. Acquired
      azole resistance in A. fumigatus has been reported since 1997 and has emerged in many
      countries, particularly in Europe, as well as on other continents. In some instances,
      acquired resistance may be driven by antifungal selection in patients receiving long-term
      therapy. Nevertheless, it seems that many azole-resistant strains originated in the
      environment due to selection by azole fungicides used in agriculture. Azole resistance in A.
      fumigatus is associated mainly with mutations in the cyp51A gene, and among several mutations
      described, the most frequent is the mutation comprising a 34-bp tandem repeat (TR34) and the
      L98H alteration. Since azoles are the recommended first-line treatment for IPA, the emergence
      of azole resistance is worrisome and has been shown to be associated with an increased rate
      of clinical failure. For these reasons, routine antifungal susceptibility testing of clinical
      isolates has been recommended recently. Nevertheless, isolates are not always retrieved in
      culture, particularly for patients with hematological malignancies. Therefore, molecular
      detection of resistance may be a major advance for the management of patients with invasive
      aspergillosis.

      The aim of this study will be to validate the new MycoGENIE A. fumigatus real-time PCR kit
      and to evaluate its performance on clinical samples for the detection of A. fumigatus and its
      azole resistance. This multiplex assay detects DNA from the A. fumigatus species complex by
      targeting the multicopy 28S rRNA gene and specific TR34 and L98H mutations in the single-copy
      number cyp51A gene of A. fumigatus.

      The study will be performed in hematological patients with high-risk of developping IA during
      the course of chemotherapy. In these patients, bi-weekly detection of GM is routinely
      performed in all centers in France. The PCR will be performed on the samples used for GM
      detection. DNA will be extracted according to the manufacturer's protocol, using the
      MycoGENIE kit for AutoMag solution. Real-time PCR for the detection of A. fumigatus DNA will
      be performed using the MycoGENIE A. fumigatus real-time PCR kit (Ademtech, Pessac, France).

      AI will be defined as proven or probable aspergillosis, according to EORTC criteria.

      For each patient, clinical data will be collected in each center. These data include: EORTC
      classification, type and duration of antifungal treatments, results of GM tests, results of
      mycological cultures, and results of PCR tests (positivity and Ct values). For each patient a
      case report form (CRF) will be filled and transfered to the investigating center for
      analysis. Sensitivity, specificity, PPV and NPV of the PCR test will be calculated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2018</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Performance of PCR for Aspergillosis diagnosis</measure>
    <time_frame>6 months</time_frame>
    <description>Determination of the performances (Sensitivity, specificity, PPV and NPV) of the kit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection of azole resistance</measure>
    <time_frame>6 months</time_frame>
    <description>Detection of TR34 and L98H mutations in the A. fumigatus single-copy number gene cyp51A.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Invasive Aspergillosis in Patients With Onco-haematological Diseases</condition>
  <arm_group>
    <arm_group_label>Hematological patients</arm_group_label>
    <description>Hematological patients at high risk for invasive aspergillosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>DNA extraction and detection of Aspergillus fumigatus in serum samples</intervention_name>
    <description>Performances diagnostic test of the real-time PCR ADEMTECH kit of DNA extraction and detection of Aspergillus fumigatus in serum samples in patients at high-risk for invasive aspergillosis (IA).</description>
    <arm_group_label>Hematological patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Human sera (serum)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hematological patients at high risk for invasive aspergillosis, who can be classified
        according to EORTC criteria
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult Patients (≥ 18 years) hospitalized in onco hematologic unit or in hematopoietic
             stem cell transplantation (HSCT) unit

          2. Patients with acute leukemia undergoing induction for AML, ALL, chimotherapy with
             neutopenia &gt;10 days or Patients undergoing allogeneic stem cell chemotherapy
             transplantation

          3. Patients with biweekly screening for GM detection in serum

        Exclusion Criteria:

          1. Patient &lt; 18 years-old (minor)

          2. Informed consent not available

          3. Patient without affiliation to French social insurance

          4. Patient without biweekly screening for GM detection in serum
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric DANNAOUI, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie-Elisabeth BOUGNOUX, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-Elisabeth BOUGNOUX, MD, PhD</last_name>
    <phone>+33 (0)1 44 49 25 45</phone>
    <email>marie-elisabeth.bougnoux@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>PRISSILE BAKOUBOULA, PhD</last_name>
    <phone>+33 (0)1 71 19 64 94</phone>
    <email>prissile.bakouboula@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Bordeaux, Groupe hospitalier</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire CALMETTES</last_name>
      <phone>+33 (0)5 57 65 65 11</phone>
      <email>claire.calmettes@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Claire CALMETTES, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle ACCOCEBERRY, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Noémie CORON, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de DIJON, Hôpital du bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis CAILLOT</last_name>
      <phone>+33 (0)3 80 29 36 45</phone>
      <email>denis.caillot@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Denis CAILLOT, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frederic DALLE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille, Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ibrahim Yakoub-Agha</last_name>
      <phone>+33 (0)3 20 44 55 51</phone>
      <email>i-yakoub-agha@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Ibrahim Yakoub-Agha, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Séverine Loridant, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes, Hôpital de Moncousu</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas GASTINNE</last_name>
      <phone>+33 (0)2 40 08 33 02</phone>
      <email>thomas.gastine@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Thomas GASTINNE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrice LE PAPE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker - Enfants maladies (AP-HP)</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Elizabeth BOUGNOUX, MD, PhD</last_name>
      <phone>+33 (0)1 44 49 25 45</phone>
      <email>marie-elisabeth.bougnoux@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Elisabeth BOUGNOUX, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Felipe SUAREZ, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de RENNES, hôpital de Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laure GOURSAUD</last_name>
      <phone>+33 (0)2 99 28 57 45</phone>
      <email>laure.goursaud@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Laure GOURSAUD, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Pierre GANGNEUX, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Suarez F, Lortholary O, Buland S, Rubio MT, Ghez D, Mahé V, Quesne G, Poirée S, Buzyn A, Varet B, Berche P, Bougnoux ME. Detection of circulating Aspergillus fumigatus DNA by real-time PCR assay of large serum volumes improves early diagnosis of invasive aspergillosis in high-risk adult patients under hematologic surveillance. J Clin Microbiol. 2008 Nov;46(11):3772-7. doi: 10.1128/JCM.01086-08. Epub 2008 Sep 24.</citation>
    <PMID>18845828</PMID>
  </reference>
  <reference>
    <citation>Dannaoui E, Gabriel F, Gaboyard M, Lagardere G, Audebert L, Quesne G, Godichaud S, Verweij PE, Accoceberry I, Bougnoux ME. Molecular Diagnosis of Invasive Aspergillosis and Detection of Azole Resistance by a Newly Commercialized PCR Kit. J Clin Microbiol. 2017 Nov;55(11):3210-3218. doi: 10.1128/JCM.01032-17. Epub 2017 Aug 16.</citation>
    <PMID>28814586</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2017</study_first_submitted>
  <study_first_submitted_qc>November 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2017</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aspergillosis,</keyword>
  <keyword>qPCR</keyword>
  <keyword>allogenic haemopoietic stem-cell transplantation</keyword>
  <keyword>leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspergillosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

